Lyell Immunopharma, Inc (LYEL)

$1.76

-0.12

(-6.38%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $1.73
    $1.88
    $1.76
    downward going graph

    1.99%

    Downside

    Day's Volatility :8.24%

    Upside

    6.38%

    downward going graph
  • $1.18
    $3.41
    $1.76
    downward going graph

    32.95%

    Downside

    52 Weeks Volatility :65.4%

    Upside

    48.39%

    downward going graph

Returns

PeriodLyell Immunopharma, IncSector (Health Care)Index (Russel 2000)
3 Months
-21.01%
8.2%
0.0%
6 Months
-6.0%
7.5%
0.0%
1 Year
-37.33%
14.3%
0.0%
3 Years
-88.57%
16.5%
-18.2%

Highlights

Market Capitalization
438.5M
Book Value
$2.37
Earnings Per Share (EPS)
-0.9
Wall Street Target Price
3.67
Profit Margin
0.0%
Operating Margin TTM
-1852500.0%
Return On Assets TTM
-18.93%
Return On Equity TTM
-32.93%
Revenue TTM
68.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-95.39999999999999%
Gross Profit TTM
84.7M
EBITDA
-218.3M
Diluted Eps TTM
-0.9
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.87
EPS Estimate Next Year
-0.94
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Lyell Immunopharma, Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 108.52%

Current $1.76
Target $3.67

Company Financials

FY19Y/Y Change
Revenue
657.0K
-
Net Income
-121.3M
-
Net Profit Margin
-18.5K%
-
FY20Y/Y Change
Revenue
7.8M
↑ 1080.52%
Net Income
-198.5M
↑ 63.73%
Net Profit Margin
-2.6K%
↑ 15896.28%
FY21Y/Y Change
Revenue
10.7M
↑ 37.31%
Net Income
-285.5M
↑ 43.81%
Net Profit Margin
-2.7K%
↓ 121.03%
FY22Y/Y Change
Revenue
84.7M
↑ 695.15%
Net Income
-4.8M
↓ 98.33%
Net Profit Margin
-5.61%
↑ 2675.15%
FY23Y/Y Change
Revenue
130.0K
↓ 99.85%
Net Income
-234.6M
↑ 4835.46%
Net Profit Margin
-180.5K%
↓ 180480.54%
Q4 FY22Q/Q Change
Revenue
48.4K
↑ 1512.87%
Net Income
2.4M
↓ 103.29%
Net Profit Margin
5.0K%
↑ 2474073.22%
Q1 FY23Q/Q Change
Revenue
65.0K
↑ 34.34%
Net Income
-132.6M
↓ 5538.77%
Net Profit Margin
-204.0K%
↓ 209086.04%
Q2 FY23Q/Q Change
Revenue
27.0K
↓ 58.46%
Net Income
-63.9M
↓ 51.83%
Net Profit Margin
-236.6K%
↓ 32583.48%
Q3 FY23Q/Q Change
Revenue
25.0K
↓ 7.41%
Net Income
-50.9M
↓ 20.41%
Net Profit Margin
-203.4K%
↑ 33217.63%
Q4 FY23Q/Q Change
Revenue
13.0K
↓ 48.0%
Net Income
-52.9M
↑ 4.08%
Net Profit Margin
-407.2K%
↓ 203741.85%
Q1 FY24Q/Q Change
Revenue
3.0K
↓ 76.92%
Net Income
-60.7M
↑ 14.62%
Net Profit Margin
-2.0M%
↓ 1615079.48%
FY19Y/Y Change
Total Assets
555.6M
-
Total Liabilities
147.6M
-
FY20Y/Y Change
Total Assets
908.3M
↑ 63.47%
Total Liabilities
189.8M
↑ 28.64%
FY21Y/Y Change
Total Assets
1.1B
↑ 24.13%
Total Liabilities
197.6M
↑ 4.1%
FY22Y/Y Change
Total Assets
937.6M
↓ 16.84%
Total Liabilities
104.3M
↓ 47.22%
FY23Y/Y Change
Total Assets
750.0M
↓ 20.0%
Total Liabilities
95.1M
↓ 8.85%
Q4 FY22Q/Q Change
Total Assets
937.6M
↓ 4.06%
Total Liabilities
104.3M
↓ 33.66%
Q1 FY23Q/Q Change
Total Assets
880.5M
↓ 6.09%
Total Liabilities
96.6M
↓ 7.37%
Q2 FY23Q/Q Change
Total Assets
835.4M
↓ 5.12%
Total Liabilities
98.5M
↑ 1.94%
Q3 FY23Q/Q Change
Total Assets
795.0M
↓ 4.83%
Total Liabilities
97.4M
↓ 1.1%
Q4 FY23Q/Q Change
Total Assets
750.0M
↓ 5.66%
Total Liabilities
95.1M
↓ 2.4%
Q1 FY24Q/Q Change
Total Assets
694.2M
↓ 7.44%
Total Liabilities
91.1M
↓ 4.22%
FY19Y/Y Change
Operating Cash Flow
39.5M
-
Investing Cash Flow
-422.4M
-
Financing Cash Flow
351.2M
-
FY20Y/Y Change
Operating Cash Flow
-160.9M
↓ 507.54%
Investing Cash Flow
-273.5M
↓ 35.25%
Financing Cash Flow
476.8M
↑ 35.78%
FY21Y/Y Change
Operating Cash Flow
-126.2M
↓ 21.52%
Investing Cash Flow
-121.6M
↓ 55.55%
Financing Cash Flow
401.2M
↓ 15.84%
FY22Y/Y Change
Operating Cash Flow
-169.6M
↑ 34.3%
Investing Cash Flow
-11.5M
↓ 90.51%
Financing Cash Flow
10.6M
↓ 97.35%
Q4 FY22Q/Q Change
Operating Cash Flow
-40.3M
↑ 8.53%
Investing Cash Flow
46.6M
↓ 181.72%
Financing Cash Flow
863.0K
↓ 81.87%
Q1 FY23Q/Q Change
Operating Cash Flow
-46.2M
↑ 14.76%
Investing Cash Flow
32.2M
↓ 31.07%
Financing Cash Flow
-69.0K
↓ 108.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-39.2M
↓ 15.26%
Investing Cash Flow
152.9M
↑ 375.56%
Financing Cash Flow
1.2M
↓ 1833.33%

Technicals Summary

Sell

Neutral

Buy

Lyell Immunopharma, Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
-13.36%
-6.0%
-37.33%
-88.57%
-88.87%
Moderna, Inc.
Moderna, Inc.
-9.25%
24.7%
2.07%
-60.09%
791.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.75%
17.85%
51.74%
87.1%
265.7%
Novo Nordisk A/s
Novo Nordisk A/s
0.36%
32.05%
75.05%
218.96%
483.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.23%
12.73%
36.59%
145.42%
176.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
1.78
NA
NA
-0.87
-0.33
-0.19
NA
2.37
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.94
31.94
1.46
44.22
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.76
48.76
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
17.07
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
Buy
$438.5M
-88.87%
1.78
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
791.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.2B
265.7%
31.94
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$633.1B
483.19%
48.76
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
176.04%
31.85
39.46%

Insights on Lyell Immunopharma, Inc

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 65.0K → 3.0K (in $), with an average decrease of 47.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -50.85M → -60.66M (in $), with an average decrease of 9.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 75.0% return, outperforming this stock by 112.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 217.8% return, outperforming this stock by 306.7%

Institutional Holdings

  • MWG Management Ltd.

    7.91%
  • Orland Properties Ltd

    5.92%
  • BlackRock Inc

    5.45%
  • Vanguard Group Inc

    5.25%
  • Foresite Capital Management IV, LLC

    3.27%
  • Wuxi AppTec Co Ltd

    3.21%

Company Information

we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.

Organization
Lyell Immunopharma, Inc
Employees
224
CEO
Dr. Richard D. Klausner M.D.
Industry
Services

FAQs